{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T21:09:48Z","timestamp":1790111388703,"version":"4.0.1"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100012331","name":"Agentschap Innoveren en Ondernemen","doi-asserted-by":"publisher","award":["HBC.2023.1009"],"award-info":[{"award-number":["HBC.2023.1009"]}],"id":[{"id":"10.13039\/100012331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ejpb.2026.115156","type":"journal-article","created":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T16:25:15Z","timestamp":1781886315000},"page":"115156","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Influence of counterion transfer on the physicochemical properties of fixed dose combinations containing bedaquiline and clofazimine"],"prefix":"10.1016","volume":"226","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5161-7911","authenticated-orcid":false,"given":"Hai Van","family":"Ngo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6778-203X","authenticated-orcid":false,"given":"Stijn","family":"Daems","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Govaerts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Aguilar-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy Van","family":"den Mooter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2026.115156_b0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijid.2024.107325","article-title":"Insights from the 2024 WHO Global Tuberculosis Report \u2013 more Comprehensive Action, Innovation, and Investments required for achieving WHO end TB goals","volume":"150","author":"Goletti","year":"2025","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.ejpb.2026.115156_b0010","unstructured":"2025 tuberculosis Global report, n.d."},{"key":"10.1016\/j.ejpb.2026.115156_b0015","unstructured":"Rifafour e-275, (2013). https:\/\/rsc.niaid.nih.gov\/sites\/default\/files\/package-insert-rifafour-april2013.pdf (accessed January 30, 2026)."},{"key":"10.1016\/j.ejpb.2026.115156_b0020","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-025-64427-6","article-title":"The role of cytochrome bc1 inhibitors in future tuberculosis treatment regimens","volume":"16","author":"Aguilar-P\u00e9rez","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejpb.2026.115156_b0025","doi-asserted-by":"crossref","DOI":"10.3390\/antibiotics12091389","article-title":"The efficacy and safety of bedaquiline in the treatment of pulmonary tuberculosis patients: a systematic review and meta-analysis","volume":"12","author":"Tong","year":"2023","journal-title":"Antibiotics"},{"key":"10.1016\/j.ejpb.2026.115156_b0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2024.123920","article-title":"A quality-by-design strategic approach for the development of bedaquiline-pretomanid nanoparticles as inhalable dry powders for TB treatment","volume":"653","author":"Patil","year":"2024","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2026.115156_b0035","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa2119430","article-title":"Bedaquiline\u2013pretomanid\u2013linezolid regimens for drug-resistant tuberculosis","volume":"387","author":"Conradie","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejpb.2026.115156_b0040","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1056\/NEJMoa2117166","article-title":"A 24-week, all-oral regimen for rifampin-resistant tuberculosis","volume":"387","author":"Nyang\u2019wa","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejpb.2026.115156_b0045","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/S2213-2600(25)00194-8","article-title":"Bedaquiline, delamanid, linezolid, and clofazimine for rifampicin-resistant and fluoroquinolone-resistant tuberculosis (endTB-Q): an open-label, multicentre, stratified, non-inferiority, randomised, controlled, phase 3 trial","volume":"13","author":"Guglielmetti","year":"2025","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.ejpb.2026.115156_b0050","doi-asserted-by":"crossref","first-page":"199","DOI":"10.4103\/0975-1483.104362","article-title":"Treating tuberculosis: time to introduce fixed-dose drug combinations","volume":"4","author":"Manikandan","year":"2012","journal-title":"J. Young Pharm."},{"key":"10.1016\/j.ejpb.2026.115156_b0055","first-page":"935","article-title":"Do fixed-dose combination pills or unit-of-use packaging improve adherence? A systematic review","volume":"82","author":"Connor","year":"2004","journal-title":"Bull. World Health Organ."},{"key":"10.1016\/j.ejpb.2026.115156_b0060","first-page":"760","article-title":"Rimstar 4-FDC Study Group, Comparison of a four-drug fixed-dose combination regimen with a single tablet regimen in smear-positive pulmonary tuberculosis","volume":"13","author":"Bartacek","year":"2009","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"10.1016\/j.ejpb.2026.115156_b0065","unstructured":"WHO, WHO operational handbook on tuberculosis. Module 4: treatment and care, n.d."},{"key":"10.1016\/j.ejpb.2026.115156_b0070","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1097\/CCM.0b013e3181e8adcc","article-title":"Systematic review of physical and chemical compatibility of commonly used medications administered by continuous infusion in intensive care units","volume":"38","author":"Kanji","year":"2010","journal-title":"Crit. Care Med."},{"key":"10.1016\/j.ejpb.2026.115156_b0075","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14020424","article-title":"Interaction and compatibility studies in the Development of Olmesartan Medoxomil and hydrochlorothiazide formulations under a real manufacturing process","volume":"14","author":"Murillo-Fern\u00e1ndez","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejpb.2026.115156_b0080","unstructured":"CHMP, Committee for Medicinal Products for Human Use (CHMP) CHMP assessment report, 2013. www.ema.europa.eu."},{"key":"10.1016\/j.ejpb.2026.115156_b0085","doi-asserted-by":"crossref","DOI":"10.3390\/antibiotics12101510","article-title":"Development of bedaquiline-loaded SNEDDS using quality by design (QbD) approach to improve biopharmaceutical attributes for the management of multidrug-resistant tuberculosis (MDR-TB)","volume":"12","author":"Jahan","year":"2023","journal-title":"Antibiotics"},{"key":"10.1016\/j.ejpb.2026.115156_b0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113562","article-title":"Optimization of the clofazimine structure leads to a highly water-soluble C3-aminopyridinyl riminophenazine endowed with improved anti-Wnt and anti-cancer activity in vitro and in vivo","volume":"222","author":"Koval","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejpb.2026.115156_b0095","doi-asserted-by":"crossref","first-page":"3480","DOI":"10.1021\/acs.molpharmaceut.7b00521","article-title":"Design and solidification of fast-releasing clofazimine nanoparticles for treatment of cryptosporidiosis","volume":"14","author":"Zhang","year":"2017","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejpb.2026.115156_b0100","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1007\/s11095-016-1870-z","article-title":"New perspectives for fixed dose combinations of poorly water-soluble compounds: a case study with ezetimibe and lovastatin","volume":"33","author":"Riekes","year":"2016","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2026.115156_b0105","article-title":"Poorly water-soluble APIs in fixed-dose combinations: development, challenges, and opportunities in manufacturing techniques","volume":"111","author":"Lesutan","year":"2025","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.ejpb.2026.115156_b0110","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.jid.2017.09.031","article-title":"The physicochemical basis of clofazimine-induced skin pigmentation","volume":"138","author":"Murashov","year":"2018","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.ejpb.2026.115156_b0115","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1021\/acs.molpharmaceut.3c00172","article-title":"Clofazimine pKa determination by potentiometry and spectrophotometry: reverse cosolvent dependence as an indicator of the presence of dimers in aqueous solutions","volume":"20","author":"Verbi\u0107","year":"2023","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejpb.2026.115156_b0120","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1002\/bcp.70163","article-title":"Extrapolation of lung pharmacokinetics of bedaquiline across species using physiologically-based pharmacokinetic modelling","volume":"91","author":"Karakitsios","year":"2025","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejpb.2026.115156_b0125","doi-asserted-by":"crossref","first-page":"7169","DOI":"10.1039\/D4AY01143K","article-title":"A sensitive, rapid and cost-effective RP-HPLC-UV method for detection and quantification of bedaquiline in physiological fluid (pH 7.4)","volume":"16","author":"Ayodele","year":"2024","journal-title":"Anal. Methods"},{"key":"10.1016\/j.ejpb.2026.115156_b0130","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s00253-007-1341-x","article-title":"Fumaric acid production by fermentation","volume":"78","author":"Roa Engel","year":"2008","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"10.1016\/j.ejpb.2026.115156_b0135","doi-asserted-by":"crossref","unstructured":"S. Das, S. Pratik, A. Datta, Crystals of Organic Acid-Bases Complexes Defy the pKa Rule Under Compression, (2024). doi: 10.26434\/chemrxiv-2024-3vwf1.","DOI":"10.26434\/chemrxiv-2024-3vwf1"},{"key":"10.1016\/j.ejpb.2026.115156_b0140","doi-asserted-by":"crossref","first-page":"6250","DOI":"10.1021\/cg301463z","article-title":"Clofazimine mesylate: a high solubility stable salt","volume":"12","author":"Bolla","year":"2012","journal-title":"Cryst. Growth Des."},{"key":"10.1016\/j.ejpb.2026.115156_b0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2020.128226","article-title":"A new salt of clofazimine to improve leprosy treatment","volume":"1214","author":"Sousa","year":"2020","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.ejpb.2026.115156_b0150","doi-asserted-by":"crossref","first-page":"8969","DOI":"10.1021\/acsomega.7b01454","article-title":"Role of biorelevant dissolution media in the selection of optimal salt forms of oral drugs: maximizing the gastrointestinal solubility and in vitro activity of the antimicrobial molecule, clofazimine","volume":"2","author":"Bannigan","year":"2017","journal-title":"ACS Omega"},{"key":"10.1016\/j.ejpb.2026.115156_b0155","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics16121545","article-title":"Effects of different weak small organic acids on clofazimine solubility in aqueous media","volume":"16","author":"Topalovi\u0107","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejpb.2026.115156_b0160","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1093\/jac\/dkae233","article-title":"Beyond the FIC index: the extended information from fractional inhibitory concentrations (FICs)","volume":"79","author":"Fatsis-Kavalopoulos","year":"2024","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ejpb.2026.115156_b0165","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1080\/10837450500299982","article-title":"Drug-drug interaction studies on first-line anti-tuberculosis drugs","volume":"10","author":"Bhutani","year":"2005","journal-title":"Pharm. Dev. Technol."},{"key":"10.1016\/j.ejpb.2026.115156_b0170","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1081\/DDC-120021772","article-title":"Behavior of decomposition of rifampicin in the presence of isoniazid in the pH range 1-3","volume":"29","author":"Sankar","year":"2003","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.ejpb.2026.115156_b0175","doi-asserted-by":"crossref","first-page":"e355","DOI":"10.1016\/S2214-109X(24)00467-4","article-title":"24-week, all-oral regimens for pulmonary rifampicin-resistant tuberculosis in TB-PRACTECAL trial sites: an economic evaluation","volume":"13","author":"Sweeney","year":"2025","journal-title":"Lancet Glob. Health"},{"key":"10.1016\/j.ejpb.2026.115156_b0180","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1093\/jac\/dky526","article-title":"A bedaquiline\/clofazimine combination regimen might add activity to the treatment of clinically relevant non-tuberculous mycobacteria","volume":"74","author":"Ruth","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ejpb.2026.115156_b0185","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.diagmicrobio.2019.02.012","article-title":"No in vitro synergistic effect of bedaquiline combined with fluoroquinolones, linezolid, and clofazimine against extensively drug-resistant tuberculosis","volume":"94","author":"Pang","year":"2019","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"10.1016\/j.ejpb.2026.115156_b0190","article-title":"Incompatibility of Y-site-administered drugs: the case of acyclovir and ciprofloxacin","volume":"3","author":"Labrosse","year":"2024","journal-title":"RPS Pharm. Pharmacol. Rep."},{"key":"10.1016\/j.ejpb.2026.115156_b0195","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1039\/D1FD00081K","article-title":"The role of solvation in proton transfer reactions: implications for predicting salt\/co-crystal formation using the \u0394pKa rule","volume":"235","author":"Cruz-Cabeza","year":"2022","journal-title":"Faraday Discuss."},{"key":"10.1016\/j.ejpb.2026.115156_b0200","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics11100502","article-title":"Inhalable dry powder of bedaquiline for pulmonary tuberculosis: in vitro physicochemical characterization, antimicrobial activity and safety studies","volume":"11","author":"Momin","year":"2019","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejpb.2026.115156_b0205","article-title":"Impact of binary\/ternary solid dispersion utilizing poloxamer 188 and TPGS to improve pharmaceutical attributes of bedaquiline fumarate","volume":"62","author":"Pardhi","year":"2021","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.ejpb.2026.115156_b0210","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.ijpharm.2015.10.026","article-title":"Dissolution performance of binary amorphous drug combinations - impact of a second drug on the maximum achievable supersaturation","volume":"496","author":"Trasi","year":"2015","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2026.115156_b0215","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1002\/jps.24528","article-title":"Thermodynamics of highly supersaturated aqueous solutions of poorly water-soluble drugs - impact of a second drug on the solution phase behavior and implications for combination products","volume":"104","author":"Trasi","year":"2015","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2026.115156_b0220","doi-asserted-by":"crossref","DOI":"10.1186\/s12879-025-11605-y","article-title":"Bedaquiline combined with clofazimine as salvage therapy for 11 patients with nontuberculous mycobacterial lung disease","volume":"25","author":"Yao","year":"2025","journal-title":"BMC Infect. Dis."}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641126001773?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641126001773?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T20:41:41Z","timestamp":1790109701000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641126001773"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":44,"alternative-id":["S0939641126001773"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2026.115156","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Influence of counterion transfer on the physicochemical properties of fixed dose combinations containing bedaquiline and clofazimine","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2026.115156","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"115156"}}